SecBot SecBot
Biotech Drug Report Generated Aug 2, 2026

Sprycel

BMY·BRISTOL MYERS SQUIBB CO
NEUTRAL
Drug Impact Rating2/10
Trial phase
Approved
Time to market
Already on the market, FDA approved June 28, 2006; now in the generic-erosion phase of its life cycle.
Why 2/10
No hard, dated catalyst for Sprycel in the next ~12 months: the drug was FDA-approved June 28, 2006 and is now an off-patent, generically-eroded product whose Q2 2026 revenue fell 27% YoY, a minor legacy line inside a ~$129B diversified BMY, so the impact score is 2 (small part of a large pipeline, nothing scheduled).
Actionable Insight NEUTRAL

Do not trade BMY on Sprycel news, the binary (approval) passed 20 years ago and its erosion is immaterial to a ~$129B market-cap company whose stock is driven by the Growth Portfolio (Opdivo, Reblozyl, Eliquis, etc.). Track it only as a line in BMY's Legacy Portfolio in quarterly filings; BMY's real near-term FDA catalysts are other drugs: iberdomide PDUFA August 17, 2026, Reblozyl March 11, 2027, and mezigdomide May 13, 2027.

Price Chart

Loading chart...

Executive Summary

Sprycel (dasatinib) is Bristol-Myers Squibb's older-generation BCR-ABL inhibitor for CML and Philadelphia chromosome-positive ALL, FDA-approved in June 2006. It is now off patent: BMY's Q2 2026 earnings materials (8-K filed July 30, 2026) report Sprycel revenue fell 27% YoY on generic erosion, within a Legacy Portfolio that was down 4% overall. For a diversified ~$129B BMY trading near $65 with a consensus "hold" rating, Sprycel is a mature, declining legacy product with no pending regulatory decision and no meaningful share-price catalyst, the approval binary passed two decades ago.

How It Works

Sprycel is an oral pill (a "tyrosine kinase inhibitor") that blocks BCR-ABL, the abnormal enzyme produced by the "Philadelphia chromosome" that drives chronic myeloid leukemia (CML) and some acute lymphoblastic leukemia (ALL). By shutting off that growth signal it slows or stops the leukemia, and it is taken daily at home.

Trial Status

No BMS-sponsored pivotal dasatinib trials appear in SecBot's ClinicalTrials.gov feed, the remaining studies are investigator-initiated Phase 2/3 efforts (e.g., OPTIM DASATINIB in CML, dasatinib+quercetin in NASH/liver fibrosis, dasatinib in aging/senescence pilots), all completed and none a company-level catalyst. Regulatory status: marketed; BMY's Q2 2026 8-K shows Sprycel revenue down 27% YoY on generic competition.

The Two-Sided Case

▲ Bull Case4
Established standard-of-care: FDA approval recorded June 28, 2006 for BMY, giving it a ~20-year commercial track record in CML and Ph+ ALL.
Still a marketed Legacy Portfolio product with franchise revenue; BMY's Q2 2026 8-K materials show the Legacy Portfolio generated $5.4B in the quarter (with Eliquis up 22% offsetting generic erosion elsewhere).
For a ~$129B market-cap BMY with analyst consensus 'hold' and mean price target $64.91 vs. ~$65.31 price, Sprycel's decline is immaterial to the stock, which is driven by the growing Growth Portfolio (Opdivo Qvantig, Reblozyl, Camzyos, Breyanzi, Opdualag).
No safety/regulatory overhang: no recalls, safety-labeling actions, or enforcement rows tied to Sprycel in SecBot's FDA action data.
▼ Bear Case4
Generic erosion is real and accelerating: BMY's Q2 2026 earnings materials report Sprycel revenue down 27% YoY, the fastest-declining named legacy drug alongside Revlimid (-49%) and Pomalyst/Imnovid (-71%).
No growth catalysts: the drug's defining binary (FDA approval) passed in 2006, and no BMS-sponsored pivotal dasatinib trials are in SecBot's clinical-trial feed, only investigator-initiated studies, so there is no label-expansion or data readout to re-rate the asset.
Competitive TKI field: dasatinib competes with multiple other marketed BCR-ABL inhibitors and now low-cost generics, pressuring volume and price in a small leukemia market (generic competition confirmed in BMY's 8-K analysis).
Legacy Portfolio overall is shrinking (-4% YoY in Q2 2026), and Sprycel sits in the portfolio BMY is explicitly transitioning away from as it pivots to Growth Portfolio products.

Upcoming Catalysts

  • None for Sprycel itself, no PDUFA, pivotal readout, or regulatory decision scheduled in the next ~12 months.
  • Company-level context only: iberdomide PDUFA Aug 17, 2026; Reblozyl PDUFA Mar 11, 2027; mezigdomide PDUFA May 13, 2027.
  • Quarterly Legacy Portfolio reporting (next 10-Q / earnings 8-K) will show continued Sprycel erosion magnitude.

Source Filing

The SecBot filing or press-release report that triggered this drug report:

BRISTOL MYERS SQUIBB CO 8-K BMY ·Originating report

Sources · 3

Hover a chip for the title
1 sec.gov2 sec.gov3 sec.gov